Stock SHPMY SHANGHAI PHARMACEUTICALS HOLDING CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Shanghai Pharmaceuticals Holding Co., Ltd Share Price Other OTC

Equities

SHPMY

US81943R1005

Pharmaceuticals

Financials

Sales 2024 * 288B 39.8B 3,307B Sales 2025 * 317B 43.75B 3,635B Capitalization 61.18B 8.44B 702B
Net income 2024 * 4.83B 667M 55.38B Net income 2025 * 5.84B 806M 66.97B EV / Sales 2024 * 0.26 x
Net Debt 2024 * 13.27B 1.83B 152B Net Debt 2025 * 19.41B 2.68B 223B EV / Sales 2025 * 0.25 x
P/E ratio 2024 *
12.8 x
P/E ratio 2025 *
11.2 x
Employees -
Yield 2024 *
2.83%
Yield 2025 *
3.5%
Free-Float 38.5%
More Fundamentals * Assessed data

Chart Shanghai Pharmaceuticals Holding Co., Ltd

Dynamic Chart

Latest news about Shanghai Pharmaceuticals Holding Co., Ltd

Shanghai Pharmaceuticals Holding Co., Ltd Announces Resignation of Chen Fashu as Non-Executive Director CI
Shanghai Pharma Gets Clinical Trial Approval for Antidepressants MT
Shanghai Pharmaceuticals' Unit Gets Nod for Raw Drug Material for Hypertension, Heart Disease; Shares Down 3% MT
Shanghai Pharmaceuticals Unit Gets Green Light to Market Cancer Drug MT
Shanghai Pharmaceuticals Gets Regulatory Nod to Trial Tumor Drug MT
Shanghai Pharmaceuticals Holding's Q1 Profit Rises 2% as Revenue Grows 6% MT
Shanghai Pharmaceuticals Holding Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Shanghai Pharma's Profit Plunges 33% in 2023 Despite 12% Revenue Growth; Shanghai Shares Rise 4% MT
Shanghai Pharmaceuticals Holding Co., Ltd Proposes Final Dividend for the Year Ended 31 December 2023, Payable Before 30 August 2024 CI
Shanghai Pharmaceuticals Holding Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Shanghai Pharmaceuticals Gets Nod to Register Amiodarone Hydrochloride Injection MT
Shanghai Pharma Names Chairman; Vice Chairman Resigns MT
Shanghai Pharmaceuticals Holding Co., Ltd Announces Executive Changes CI
Shanghai Pharma Unit's Citicoline Sodium Injection Passes Regulatory Evaluation MT
Shanghai Pharmaceuticals Holding Co., Ltd Announces Change of Principal Place of Business in Hong Kong CI
More news

Press releases Shanghai Pharmaceuticals Holding Co., Ltd

Shionogi & Co., Ltd. - Notice Regarding a License Agreement for Promotion of Ensitrelvir Fumaric Acid, a Therapeutic Drug for COVID-19, in China AQ
Shanghai Pharmaceuticals : REPLY SLIP FOR HOLDERS OF H SHARE ATTENDING THE EXTRAORDINARY GENERAL MEETING PU
Shanghai Pharmaceuticals : The Fortune 500 company Shanghai Pharmaceuticals enters the dental equipment market by acquiring Finnish dental equipment company Fimet Oy and its operations in Finland and China AQ
Shanghai Pharmaceuticals : CONNECTED TRANSACTION PROPOSED NON-PUBLIC ISSUANCE OF A SHARES PU
Shanghai Pharmaceuticals : SUPPLEMENT ANNOUNCEMENT TO THE 2019 SHARE OPTION INCENTIVE SCHEME OF THE COMPANY PU
More press releases

News in other languages on Shanghai Pharmaceuticals Holding Co., Ltd

Fábricas de Shanghái alistan reapertura mientras la ciudad se apresta a aliviar confinamiento
Tesla y otras empresas preparan la reanudación de la actividad en Shanghái
Ardian lance la vente de l'allemand Riemser Pharma
Shanghai Pharmaceuticals : Vers une cession du fabricant américain de génériques Alvogen
Shanghai Fosun Pharmaceutical : Arbor courtisé par deux laboratoires chinois
More news

Managers and Directors - Shanghai Pharmaceuticals Holding Co., Ltd

Managers TitleAgeSince
Yong Zhong Li PSD
 President 54 27/19/27
Bo Shen PSD
 President 51 05/13/05
Ye Lu IRC
 Investor Relations Contact 35 01/16/01
Members of the board TitleAgeSince
Bo Shen PSD
 President 51 05/13/05
Yong Zhong Li PSD
 President 54 27/19/27
Manson Fok BRD
 Director/Board Member 67 27/19/27
More insiders

Company Profile

Shanghai Pharmaceuticals Holding Co Ltd is a China-based company principally engaged in pharmaceutical industry, distribution and retail business. The Company's products include innovative drugs, chemical drugs, traditional Chinese medicines and rare disease drugs. The Company's products are mainly used in the cardiovascular system, digestive tract and metabolism, systemic anti-infection, central nervous system, anti-tumor and immunomodulators, musculoskeletal system and respiratory system. In addition, the Company also provides medical logistics and warehousing services. The Company distributes its products both in the domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
29/08/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
MCKESSON CORPORATION Stock McKesson Corporation
+22.77% 74.04B
CARDINAL HEALTH, INC. Stock Cardinal Health, Inc.
-1.66% 24.18B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
+3.42% 8.46B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-23.71% 7.64B
H. LUNDBECK A/S Stock H. Lundbeck A/S
+14.04% 5.33B
GALENICA AG Stock Galenica AG
+1.92% 4.12B
EBOS GROUP LIMITED Stock EBOS Group Limited
-6.90% 3.92B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
+5.56% 3.89B
CHINA NATIONAL MEDICINES CORPORATION LTD. Stock China National Medicines Corporation Ltd.
+18.80% 3.54B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. 601607 Stock
  4. SHPMY Stock